3518 related articles for article (PubMed ID: 11109974)
1. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.
Stomati M; Monteleone P; Casarosa E; Quirici B; Puccetti S; Bernardi F; Genazzani AD; Rovati L; Luisi M; Genazzani AR
Gynecol Endocrinol; 2000 Oct; 14(5):342-63. PubMed ID: 11109974
[TBL] [Abstract][Full Text] [Related]
2. Adrenal function under long-term raloxifene administration.
Genazzani AR; Lombardi I; Borgioli G; di Bono I; Casarosa E; Gambacciani M; Palumbo M; Genazzani AD; Luisi M
Gynecol Endocrinol; 2003 Apr; 17(2):159-68. PubMed ID: 12737677
[TBL] [Abstract][Full Text] [Related]
3. Long-term low-dose oral administration of dehydroepiandrosterone modulates adrenal response to adrenocorticotropic hormone in early and late postmenopausal women.
Genazzani AR; Pluchino N; Begliuomini S; Stomati M; Bernardi F; Pieri M; Casarosa E; Palumbo M; Genazzani AD; Luisi M
Gynecol Endocrinol; 2006 Nov; 22(11):627-35. PubMed ID: 17145649
[TBL] [Abstract][Full Text] [Related]
4. One-year therapy with 10mg/day DHEA alone or in combination with HRT in postmenopausal women: effects on hormonal milieu.
Pluchino N; Ninni F; Stomati M; Freschi L; Casarosa E; Valentino V; Luisi S; Genazzani AD; Potì E; Genazzani AR
Maturitas; 2008 Apr; 59(4):293-303. PubMed ID: 18394829
[TBL] [Abstract][Full Text] [Related]
5. Endocrine, neuroendocrine and behavioral effects of oral dehydroepiandrosterone sulfate supplementation in postmenopausal women.
Stomati M; Rubino S; Spinetti A; Parrini D; Luisi S; Casarosa E; Petraglia F; Genazzani AR
Gynecol Endocrinol; 1999 Feb; 13(1):15-25. PubMed ID: 10368794
[TBL] [Abstract][Full Text] [Related]
6. Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids.
Genazzani AD; Stomati M; Bernardi F; Pieri M; Rovati L; Genazzani AR
Fertil Steril; 2003 Dec; 80(6):1495-501. PubMed ID: 14667889
[TBL] [Abstract][Full Text] [Related]
7. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
[TBL] [Abstract][Full Text] [Related]
8. Pituitary function and DHEA-S in male acne and DHEA-S, prolactin and cortisol before and after oral contraceptive treatment in female acne.
Palatsi R; Reinilä M; Kivinén S
Acta Derm Venereol; 1986; 66(3):225-30. PubMed ID: 2426899
[TBL] [Abstract][Full Text] [Related]
9. [Defects of adrenal steroidogenesis in patients with hirsutism].
Salinas Vert I; Audí Parera L; Granada Ybern ML; Lucas Martín A; Pizarro Lozano E; Foz Sala M; Sanmartí Sala A
Med Clin (Barc); 1998 Feb; 110(5):171-6. PubMed ID: 9547720
[TBL] [Abstract][Full Text] [Related]
10. Effect of exogenous estrogen on serum pregnenolone, cortisol, and androgens in postmenopausal women.
Abraham GE; Maroulis GB
Obstet Gynecol; 1975 Mar; 45(3):271-4. PubMed ID: 163457
[TBL] [Abstract][Full Text] [Related]
11. Long-term low-dose dehydroepiandrosterone replacement therapy in aging males with partial androgen deficiency.
Genazzani AR; Inglese S; Lombardi I; Pieri M; Bernardi F; Genazzani AD; Rovati L; Luisi M
Aging Male; 2004 Jun; 7(2):133-43. PubMed ID: 15672938
[TBL] [Abstract][Full Text] [Related]
12. Levels of DHEA and DHEAS and responses to CRH stimulation and hydrocortisone treatment in chronic fatigue syndrome.
Cleare AJ; O'Keane V; Miell JP
Psychoneuroendocrinology; 2004 Jul; 29(6):724-32. PubMed ID: 15110921
[TBL] [Abstract][Full Text] [Related]
13. Sex hormone-binding globulin as a marker of the effect of hormonal treatment in Turner's syndrome.
Hampl R; Snajderova M; Lebl J; Lisa L; Dvorakova M; Hill M; Sulcova J; Starka L
Endocr Regul; 2001 Mar; 35(1):17-24. PubMed ID: 11308992
[TBL] [Abstract][Full Text] [Related]
14. Anti-interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled study.
Straub RH; Härle P; Yamana S; Matsuda T; Takasugi K; Kishimoto T; Nishimoto N
Arthritis Rheum; 2006 Jun; 54(6):1778-85. PubMed ID: 16729287
[TBL] [Abstract][Full Text] [Related]
15. Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women.
Diamond P; Cusan L; Gomez JL; Bélanger A; Labrie F
J Endocrinol; 1996 Sep; 150 Suppl():S43-50. PubMed ID: 8943786
[TBL] [Abstract][Full Text] [Related]
16. Effect of different hormonal replacement therapies on circulating allopregnanolone and dehydroepiandrosterone levels in postmenopausal women.
Bernardi F; Pieri M; Stomati M; Luisi S; Palumbo M; Pluchino N; Ceccarelli C; Genazzani AR
Gynecol Endocrinol; 2003 Feb; 17(1):65-77. PubMed ID: 12724021
[TBL] [Abstract][Full Text] [Related]
17. Ovarian and adrenal contributions to peripheral steroid levels in postmenopausal women.
Maroulis GB; Abraham GE
Obstet Gynecol; 1976 Aug; 48(2):150-4. PubMed ID: 133306
[TBL] [Abstract][Full Text] [Related]
18. [Study on relationship between endogenous androgens and insulin resistance at the different stages of postmenopause].
Cao YK; Zhang SF; Zou SE; Xia X; Xu LN
Zhonghua Fu Chan Ke Za Zhi; 2013 Oct; 48(10):740-4. PubMed ID: 24406129
[TBL] [Abstract][Full Text] [Related]
19. Mild adrenal and ovarian steroidogenic abnormalities in hirsute women without hyperandrogenemia: does idiopathic hirsutism exist?
Escobar-Morreale HF; Serrano-Gotarredona J; García-Robles R; Sancho J; Varela C
Metabolism; 1997 Aug; 46(8):902-7. PubMed ID: 9258272
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of dehydroepiandrosterone and its metabolites after long-term oral dehydroepiandrosterone treatment in postmenopausal women.
Stanczyk FZ; Slater CC; Ramos DE; Azen C; Cherala G; Hakala C; Abraham G; Roy S
Menopause; 2009; 16(2):272-8. PubMed ID: 19098687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
